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Abstract
Tanapox virus (TPV) belongs to the genus Yatapoxvirus and causes a relatively benign zoonotic disease in man, with symptoms that resemble a
mild version of human monkeypox. In order to investigate the underlying mechanisms of TPV pathogenesis, the tropism and replication
characteristics of TPV were examined in a variety of primary human cells. A GFP expressing TPV (TPV-GFP) was constructed and used to infect
primary human dermal fibroblasts (pHDFs) and peripheral blood mononuclear cells (PBMCs), both of which are believed to be major in vivo
targets of poxvirus infection. pHDFs fully supported productive replication and cell–cell spread of TPV-GFP. However, induction of cell cycle
arrest in pHDFs by contact mediated inhibition or rapamycin treatment eliminated the ability of TPV to fully stimulate cell cycle progression and
dramatically reduced viral replication. TPV-GFP-infected human PBMCs were screened for permissiveness by FACS analysis. CD14+ cells
(monocytes) were the primary cellular target for TPV infection. A small proportion of CD3+ cells (T cells) were positive for GFP expression, yet
TPV was not able to replicate and spread in cultured peripheral blood lymphocytes, regardless of their state of activation. Primary human
monocytes, however, demonstrated robust TPV replication, yet these cells no longer supported replication of TPV once they differentiated into
macrophages. This unique ex vivo tropism of TPV gives key insights into the basis for the self-limiting pathogenicity of TPV in man.
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Tanapox virus (TPV) is a member of the Yatapoxvirus genus
of poxviruses that is characterized by its ability to cause
relatively mild monkeypox-like infections of primates, includ-
ing man (Damon, 2007; Knight et al., 1989). TPV is endemic to
equatorial Africa and causes occasional zoonotic infections in
humans, likely transmitted through biting arthropod vectors, but
direct human-to-human transmission of TPV has never been
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doi:10.1016/j.virol.2007.06.019followed by the development of one or few inflamed nodule-
like lesions and concurrent lymphadenopathy. Maximum lesion
size is reached by approximately 2 weeks and resolution of the
lesion usually occurs within 6 weeks (Jezek et al., 1985).
This self-limiting poxvirus infection is contrasted with
Variola virus (VARV), which causes smallpox and is a systemic
disease of comparatively short duration with significant
morbidity and mortality (Damon, 2007). From the study of
other orthopoxviruses, it is likely that VARV, like other
orthopoxviruses, spreads from the initial site of infection
(usually the skin or respiratory route), through infected
dendritic cells that traffic to the draining lymph node
(Damon, 2007). Primary viremia is caused by viral replication
within the lymph node and causes subsequent infection of
secondary sites through the blood, including the spleen, liver,
and bone marrow. Secondary viremia from these sites causes
other localized infections, which leads to the characteristic
pock lesions or rash (Damon, 2007). Studies with Vaccinia
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the main targets of orthopoxvirus replication within the blood
and may be primarily responsible for systemic spread of the
highly pathogenic poxviruses (Chahroudi et al., 2005; Sanchez-
Puig et al., 2004; Yu et al., 2006). Both the dermal and
epidermal layers of the skin have been implicated in pock
formation, with viral replication within the dermal layer being
important for systemic spread of the virus from the periphery
(Damon, 2007).
At the other end of the pathogenic spectrum of poxviruses in
man lies Molluscum contagiosum virus (MOCV), for which
viral replication is highly restricted to differentiating keratino-
cytes, resulting in small benign lesions as the only clinical
feature in immunocompetent hosts (Gottlieb and Myskowski,
1994; Lewis et al., 1997). Lesions may persist for months
without any immune cell infiltrate and, as a result, are noted for a
lack of inflammation at sites of viral infection (Heng et al.,
1989).
Findings from these viruses suggests that cellular tropism
of poxviruses that infect man may be closely linked to its
pathogenicity. Poxvirus tropism of cultured cells is largely
mediated at the intracellular level and it is generally accepted
that poxviruses, through receptor non-specific interactions, are
able to bind and enter most cell types and express at least
some early gene products (Moss, 2006). In fact, resting
human naive T-cells are one of the few cell types which have
been reported to be refractory to the binding and/or entry of
vaccinia virus (Chahroudi et al., 2005). Permissiveness of
poxviruses is therefore thought to be controlled at the level of
the intracellular environment, which varies based on cell type,
cellular activation state, and various induced anti-viral
signaling cascades (McFadden, 2005). A successful poxvirus
infection regulates the intracellular signaling environment of
the infected cell to ensure both the efficient transcription and
translation of viral genes that lead to the production of
progeny virions, and also to mitigate the various anti-viral
cellular responses.
One of the most intricately regulated cell processes is the
cell cycle, in which chromosomes are replicated (S) and then
are segregated into two daughter cells through mitosis (M).
Regulatory checkpoints at G0, G1, and G2, allow for rigorous
control of replication through the cell cycle (reviewed by
Murray, 2004). Many viruses favor cells in a certain phase of
the cell cycle in order to provide an adequate environment for
viral replication. As such, stimulating progression through the
cell cycle is a key adaptive strategy for many viruses, inclu-
ding cytomegalovirus (Castillo and Kowalik, 2004), adeno-
virus (Berk, 2005), and poxviruses (Johnston et al., 2005;
Wali and Strayer, 1999). For example, VACV infection can
increase transit of cells out of G1 into S phase through a
modulation of cyclin and cyclin-dependent kinase levels (Wali
and Strayer, 1999). Similarly, the Myxoma virus (MYXV) M-
T5 host range protein has been shown to interact with host
cell cullin-1, and a MYXV construct deficient in M-T5 was
shown to be unable to transition infected cells out of cell cycle
arrest, correlating with a reduction in MYXV replication
(Johnston et al., 2005).The current study was initiated to analyze TPV infection in
primary human cells to correlate its cellular tropism in human
cells ex vivo to its pathogenicity profile in man. A TPV
expressing EGFP from a synthetic early/late poxvirus pro-
moter was constructed to aid in the identification of TPV-
infected cells, which was used to assess replication efficiencies
in primary human cells in vitro. Various modulations of cell
states were also tested, including differentiation, activation,
and cell cycle arrest induced by treatment with cytostatic drug
rapamycin, to evaluate their role in TPV replication. The
cellular tropism profile of TPV in primary human cells is
discussed as a potential ex vivo surrogate system to ratio-
nalize the restricted spread of TPV throughout the infected
host and better understand its self-limiting pathogenesis pro-
file in man.
Results
Optimal replication temperature of TPV-GFP is 33–35 °C
TPV was engineered to express EGFP from a synthetic
early/late promoter. An expression cassette containing the
synthetic early/late promoter and EGFP open reading frame
was inserted between 5L and 6L in the TPV genome. TPV 5L
is predicted to encode a ubiquitin ligase and TPV 6L is of
unknown function. TPV-GFP was plaque purified and verified
to be pure by PCR analysis of the viral genomic DNA (data not
shown). It has been previously reported that TPV grows
equally well at both 33 °C and 37 °C, reaching a maximum titer
at 96 h post-infection (hpi), in OMK cells (Mediratta and
Essani, 1999). However, when tested in OMK cells, single step
replication curves of TPV at 33 °C and 37 °C show a decrease
in virus progeny at late time points only at the higher
temperature (Fig. 1A). Single step replication curves were
repeated for TPV-GFP and were carried out at three
temperatures: 33 °C, 35 °C, and 37 °C. TPV-GFP grows
poorly, if at all, at 37 °C; however, at both 33 °C and 35 °C,
TPV-GFP replicates productively with an approximate 2-log
increase in infectious progeny (Fig. 1B). Since TPV-GFP
replication appears to be highly sensitive to temperature,
subsequent experiments with primary human cells were
performed at 33 °C.
Cycling, but not growth arrested, primary human dermal
fibroblasts are permissive for TPV-GFP
We observed that primary human dermal fibroblasts
(pHDFs) that had reached confluence and were in a quiescent
state supported only low levels of TPV-GFP replication,
accompanied by reduced GFP expression. To investigate this
further, pHDFs, either growing exponentially or quiescent,
were infected with TPV-GFP at an MOI of 3 and TPV
replication kinetics were analyzed over 4 days. Virus from the
indicated time points was collected and titrated on OMK cells
(Fig. 2). A 40-fold decrease in progeny virus yield was
observed from the quiescent HDFs as compared to exponen-
tially growing pHDFs. To further investigate the idea that
Fig. 2. Cell cycle blockade inhibits TPV-GFP replication in primary HDFs.
Primary HDFs were either growing, quiescent through contact-mediated
inhibition or pretreated with rapamycin (20 nM) for 16 h when they were
infected with TPV-GFP at an MOI of 3. Cells were collected at the indicated
time points and samples were titrated in triplicate on OMK cells.
Fig. 1. Replication kinetics of (A) TPV and (B) TPV-GFP in OMK cells at
various temperatures. OMK cells were infected at an MOI of 3. After 1 h, the
inoculum was removed and the medium was replaced. Cells were collected at
the indicated time points and samples were titrated in triplicate on OMK cells.
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pHDFs treated with the drug rapamycin were used. Rapamycin
is a highly specific inhibitor of mTOR and treatment with this
drug causes arrest in the G1 stage of cell cycle in many types of
cells, including pHDFs (Inoki and Guan, 2006). Virus
replication in cells treated with rapamycin was found to be
particularly restricted, especially at early time points, but
reaches a final level similar to quiescent pHDFs by 4 days post-
infection (Fig. 2). Interestingly, rapamycin has recently been
shown to have the opposite effect on the virus replication of
another poxvirus, myxoma virus, in human cancer cells that
have altered intracellular signaling pathways (Stanford et al.,
2007). In contrast, TPV is non-permissive in these particular
human cancer cell lines (data not shown).
In order to quantify the cell cycle changes caused by these
treatments, cells were collected, genomic DNA was stained
with propidium iodide, and cells were analyzed by FACS (Fig.
3A). Prior to infection, growing pHDFs showed a typical
distribution in the cell cycle, with G1 being the majority, and
the rest of the cells in S or G2. Infection of cycling pHDFs
caused an increase in the number of cells in the S and G2phases of the cell cycle, implying that TPV infection stimulates
cell cycle progression. In contrast, both quiescent cells and
pHDFs treated with rapamycin accumulated in the G1 phase
prior to infection. After TPV infection, quiescent cells
accumulated in early S phase but did not proceed through
the cell cycle to accumulate in G2. Cells treated with
rapamycin, however, did not seem to experience any
significant change over the time of the experiment, a
consequence of their drug induced arrest in G1 that the virus
is unable to reverse (Fig. 3A). Growth phase distribution of
uninfected cells did not vary over the course of the experiment
(Fig. 3B).
Multistep replication curves were also performed with
growing and quiescent pHDFs to examine the effect of cellular
cycling on TPV cell-to-cell spread. The inherent infectivity of
the virus was not grossly compromised in the quiescent pHDF
since a comparable number of GFP positive foci of infection
are present in both treatments (Fig. 4A). As in the single step
replication curves, TPV propagation in the growing and
quiescent pHDFs followed similar early kinetics of growth up
to 48 hpi and then a decrease in subsequent progeny titers was
detected (Fig. 4B). However, there was reduced fluorescence
intensity of the GFP and smaller foci in the quiescent pHDFs
as compared to growing pHDFs (Fig. 4A). Additionally, the
cytopathic effect of the virus in the quiescent cells was
markedly reduced, even at day 7 (Fig. 4A). To quantify the
difference in infection and fluorescence intensity, pHDFs at 7
days post-infection were analyzed by FACS. Growing pHDFs
were over 98% positive for GFP expression and had a mean
fluorescence intensity of over 1500. However, infected
quiescent pHDFs were approximately 60% positive for GFP
expression, with a mean fluorescence intensity of below 200
(Fig. 4C).
Fig. 3. Cell cycle analysis of (A) TPV-GFP-infected and (B) uninfected HDFs. Growing, quiescent, or rapamycin treated cells were infected at an MOI of 3. Cells were
collected at the indicated time points, stained with PI, and analyzed by flow cytometry. Histograms showing populations of cells in various stages of the cell cycle are
shown (A; top row). Curves were analyzed using Flo-Jo software and distribution of cells within the cell cycle is shown (bottom row).
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PBMCs
To further this avenue of investigating infection in primary
cells, human peripheral blood mononuclear cells (PBMCs) were
freshly isolated from donors, purified, and infected with TPV-
GFP at an MOI of 3. Cells were harvested at 24 and 72 hpi,
stained for CD3 and CD14, markers of T-cells and monocytes,
respectively, and analyzed by FACS (Fig. 5). CD14+ cells were
the main target of infection for TPV-GFP in PBMCs, showing
prolonged high level GFP expression in approximately 20% of
PBMCs (84–94% of CD14+ cells). However, CD14lo expres-
sing cells were not infected as readily as CD14hi expressing
cells, but did show some GFP expression by 72 hpi. CD3+ cells
were not infected nearly as readily as CD14+ cells; however 3.2to 3.9% of PBMCs (6–8% of CD3+ cells) were infected and
expressed a high level of GFP (Fig. 5).
The adherent cell fraction of PBMCs is highly permissive for
TPV-GFP infection
In order to correlate the previous FACS data to viral
replication, CD14+ cells and lymphocytes were separated using
an adherence step. Additionally, to investigate the roles of
activation and differentiation in viral replication, monocytes
were cultured for 7 days to allow for differentiation into
macrophages (Andreesen et al., 1990) and PBLs were activated
with PHA. These cells were infected at an MOI of 3 and virus
was collected at various time points (Fig. 6). Neither activated
nor naive PBLs were able to support TPV-GFP replication by
Fig. 4. Cell cycle progression is critical for efficient TPV-GFP replication and spread. Quiescent or growing primary HDFs were infected at low MOI (0.01).
(A) Fluorescent microscope pictures were acquired at time points indicated. (B) Cells were collected at indicated time points and titrated on OMK cells in
triplicate. Dashed line indicates detection limit for the assay. (C) At endpoint (168 hpi), cells were collected and analyzed by flow cytometry. Percent positive
cells (line) and mean fluorescence intensity (bars) are shown.
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kinetics were extremely robust in the freshly isolated
monocytes as compared to either OMK or pHDF cells. TPV-
GFP grew to yields of approximately 2.5 orders of progeny
increase by 24 hpi, which is essentially the maximum since the
amount of virus was similar to that obtained at 72 hpi.
Interestingly, macrophages failed to support TPV-GFP replica-
tion (Fig. 6).
Discussion
It is thought that TPV is primarily transmitted from an
unknown animal reservoir to humans by biting insects.
Therefore, upon infection, the virus has access to cells of the
blood and skin adjacent to the area of the bite. However, the
virus rarely causes more than 2 or 3 external skin nodules, and
in 80% of infections, there is only a single lesion detected (Jezek
et al., 1985). It is unknown why TPV is unable to cause
clinically significant, systemic infection in contrast to certain
other orthopoxvirus counterparts, like monkeypox. This study
analyzes TPV tropism and replication efficiency in primary
human cells to establish an ex vivo model to study TPV cellular
tropism in man. TPV expressing GFP was constructed as a tool
to examine the ability of TPV various primary human cell types.
At an optimal temperature of 33–35 °C, we found that TPV-
GFP was able to replicate efficiently in pHDFs that were in anexponential growth phase. However, cell cycle blockade either
by contact-mediated growth inhibition or treatment with
rapamycin, created an intracellular environment that did not
allow for efficient TPV replication. Analysis of the permissive
cells of the blood suggests that monocytes are the primary
cellular vehicle for spread of the virus to secondary sites.
Despite previous reports stating that TPV grows well at
37 °C (Mediratta and Essani, 1999), TPV seems to be somewhat
sensitive to temperatures above 35 °C. This sensitivity is more
obvious when using the TPV-GFP clones, likely due to
overexpression of GFP causing cell stress. This effect is not
seen at the lower temperatures tested. The implications of this
temperature sensitivity may help explain the self-limiting
pathogenesis of the TPV in man. In primates, including
humans, TPV causes only a few lesions that tend to regress
over several weeks. It is possible that this is primarily due to an
inefficiency of TPV spread internally due to a higher core body
temperature, especially considering the nature of the typical
TPV-associated febrile illness. As a result, the virus may be
restricted to replicating efficiently only at the periphery.
Lack of efficient systemic viral spread notwithstanding,
monocytes from the adherent fraction of PBMCs are highly
permissive to TPV infection. The observed rapid replication
within the primary human monocytes may allow some spread of
TPV in naturally occurring infections, and their infection may
also be the cause of the pro-inflammatory cytokines that drive
Fig. 5. TPV-GFP primarily infects CD14+ cells in whole PBMC preparations. PBMCs were isolated and infected at an MOI of 3 and harvested at 24 or 72 h. Cells were
fixed and stained for either CD3 or CD14. Representative scatter plots are shown including the percentage of cells that lie within each gate.
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traffic of infected monocytes to the draining lymph node is
likely the main culprit in inducing local lymphadenopathy.
VACV has been characterized to also primarily infect mono-
cytes (Sanchez-Puig et al., 2004). However, VACV was alsofound to infect a proportion of T-cells, B-cells, and NK cells
(Sanchez-Puig et al., 2004). Interestingly, other groups have
demonstrated that activated CD3+ leukocytes are productively
infected by VACV but resting naive T-cells are poorly infected
due to some restriction of either binding or entry (Chahroudi et
Fig. 6. TPV-GFP replicates in adherent monocytes but is unable to replicate in
differentiated macrophages. Monocytes and macrophages were infected at an
MOI of 3 and cells were collected at the indicated time points. Samples were
titrated on OMK cells in triplicate.
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of circulating lymphocytes may be required for the systemic
spread of poxviruses in general. In the case of TPV, a small
percentage of human CD3+ leukocytes are consistently
infected, as measured by GFP expression. However, the failure
to support TPV replication as measured by an absence of
increase in progeny virus suggests that this is not a productive
TPV infection in T-cells, even in lymphocytes activated with
PHA. Other subsets of mononuclear cells may be infected but
not to any significant degree since CD14-infected cells only
represent approximately 3% of cells, similar to the fraction of T-
cells that are infected.
pHDFs were used to model TPV infection at the skin. While
infection in cycling pHDFs resulted in the production of
progeny TPV, cells that were cell cycle arrested only poorly
supported viral replication. The effects of cell cycle arrest
through contact inhibition or rapamycin treatment, however,
were not identical. Either treatment alone caused the accumula-
tion of cells in G1; however, upon TPV infection, cells arrested
through contact inhibition progressed into S phase but seemed
to be blocked during DNA synthesis, which resulted in
accumulation of cells in S phase. This corresponds to the viral
replication kinetics since TPV replication paralleled that of the
actively dividing cell population until 48 hpi. Once the cells had
finished accumulating in S phase, the viral titer remained
unchanged for the remainder of the time course experiments.
Perhaps even more striking were the detrimental effects on viral
gene expression and spread of TPV due to cell cycle arrest.
Virus spread to neighboring cells still occurred during these
experiments, thus it is likely that the depression of viral gene
expression simply slows the replication of the virus and does
not block replication at a particular stage.
In contrast, rapamycin treated pHDFs showed evidence of
only minimal TPV replication and most cells remained in G1
throughout the experiment indicating effective G1 arrest by the
drug. As a consequence, the TPV replication curve was delayed,before reaching the same low-level of TPV progeny observed
with quiescent pHDFs. This is an interesting result, considering
the opposite effect that rapamycin has on the replication of
myxoma virus in human cancer cell lines (Stanford et al., 2007).
This difference is likely due to the altered cell cycle and
intracellular signaling milieu in tumor cells, and to the differing
cellular requirements of these two poxviruses.
The restricted tropism of TPV to non-quiescent fibroblasts
and monocytes gives significant clues into the modest
pathogenicity of this virus in man. Without significant
amplification of TPV within lymph node T cells, there is little
of an internal cellular reservoir of virus to cause significant
secondary viremia and delivery of virus to secondary skin sites,
resulting in secondary pock formation. In addition, TPV
replication in monocytes likely results in the acute febrile
illness frequently reported early in TPV infection, and the viral
temperature sensitivity may indicate that efficient virus
replication occurs only at the periphery. In contrast, the more
complex and devastating systemic effects of the more highly
pathogenic poxviruses in man, like monkeypox virus and
variola virus, are likely tied to their unique ability to replicate




Owl monkey kidney (OMK) cells were obtained from ATCC
(CRL-1556) and were maintained in Eagle's minimum essential
medium with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate,
0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate,
100 U penicillin/ml, 100 μg streptomycin/ml, and 10% fetal
bovine serum. Neonatal primary human dermal fibroblasts
(pHDFs) were obtained from Cascade Biologics and were
maintained in medium 106 with low serum growth supplement
as recommended by the supplier (Cascade Biologics). pHDFs
were cultured no more than 16 population doublings. Human
peripheral blood mononuclear cells (PBMCs) were isolated by
venous puncture of normal healthy donors and separated on
Histopaque-1077 (Sigma). The PBMC layer was removed and
washed 3 times in PBS and maintained in RPMI 1640 with
2 mM L-glutamine, 100 U penicillin/ml, 100 μg streptomycin/
ml, and 20% fetal bovine serum (Complete RPMI). All cells
were grown at 37 °C. Quiescence in HDFs was induced by
allowing cells to grow to confluence and then cultured at least
two more days. Growing cells were infected at approximately
50% confluence to ensure that all cells were actively growing.
In some experiments, growing cells were pretreated with
20 mM rapamycin (Sigma) for 16 h. In addition, rapamycin was
replaced each time the medium was replaced.
Cell separation and preparation
To isolate monocyte and lymphocyte fractions from PBMCs,
freshly isolated cells were allowed to adhere to surface modified
cell culture dishes (Becton Dickinson Primaria) for 2 h at 37 °C.
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with PBS and collected by centrifugation at 300×g. Monocytes
remained attached to the cell culture dish surface. To activate
PBLs, they were treated with 1 μg/ml phytohemagglutinin
(Sigma) for 24 h. They were then collected by centrifugation
and washed 3 times with complete medium. Monocytes were
left in culture for 7 days in complete RPMI media to allow for
differentiation into macrophages. The medium was changed
every 2 days.
Generation of TPV expressing EGFP
To produce a TPV construct that expressed EGFP under a
synthetic early/late promoter, sequences flanking the intergenic
region between 5L and 6L were amplified from genomic DNA





(PstI underlined). The PCR products were cloned into
pGEM-T easy (Promega) and sequenced. These constructs
were amplified and cloned into pBluescript flanking an EGFP
cassette under the synthetic early/late promoter to produce
pBS:TPV-GFP.
OMK cells were infected with TPV (strain Kenya) at an MOI
of 0.1 and then transfected with pBS:TPV-GFP. Infected cells
were collected after 72 h and subjected to 3 cycles of freeze/
thaw and sonication. Virus was plaque purified on OMK cells
by picking green fluorescent foci over 5 rounds. TPV-GFP was
amplified and determined to be pure by PCR of genomic DNA.
TPV replication curves
Single step replication curves were performed by infecting
cells in serum free medium at an MOI of 3 at 27 °C for 1 h
except for infection of PBMCs, which was done at 37 °C. Virus
inoculum was removed and replaced with complete medium;
this was considered time 0. Multistep replication curves were
performed similarly except infecting cells at an MOI of 0.01
instead of 3. Medium was replaced at day 4 of the multistep
replication curve to ensure adequate nutrients. Incubators were
calibrated immediately before the experiment and temperature
was monitored continuously throughout the experiments. Cells
were collected as the specified time points and frozen. Virus-
infected cells were subjected to 3 cycles of freeze/thaw and
were then sonicated to release virus. Cell lysates were used
to determine virus titer OMK cells in triplicate. Fluorescent
foci were enumerated and graphed using Excel software
(Microsoft).
FACS analysis
Cells were harvested either by trypsinization for pHDF cells,
or by scraping for PBMCs, and collected by centrifugation at
300×g for 10 min. Cells were washed in PBS. One of each
duplicate sample PBMCs was stained with either CD14-APC(FL-4) or CD3-APC (Caltag Laboratories) to minimize
compensation issues due to GFP (FL-1) expression. Isotype
control was a mouse IgG2a-APC antibody (ebioscience). Cells
were then either fixed in ethanol, to quench GFP expression for
cell cycle analysis, or using the cytofix/cytoperm kit as per the
manufacturer's instructions (Becton Dickinson). Cells were
analyzed on a FACS Caliber (Becton Dickinson), with appro-
priate compensation. Data were analyzed using Flo-Jo software
(Tree Star).
Cell preparation for analysis of cell cycle
Approximately 1×106 cells were collected in PBS and fixed
in cold ethanol (50% final concentration) for a minimum of 24 h
at 4 °C. Fixed cells were washed in PBS and incubated covered
at room temperature for 30 min in 0.5 ml of PBS containing
50 μg/ml propidium iodide and 50 μg/ml RNase A. Cells were
analyzed on a FACS Caliber (Becton Dickinson). Pulse width
and area were used to eliminate doublets and debris and curves
were produced and analyzed using Flo-Jo software.
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